MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Fragile X syndrome presenting with levodopa unresponsive parkinsonism

J. Mayer, J. Panicker, S. Alusi (Liverpool, United Kingdom)

Meeting: 2019 International Congress

Abstract Number: 460

Keywords: Fragile X tremor ataxia syndrome, Parkinsonism

Session Information

Date: Monday, September 23, 2019

Session Title: Genetics

Session Time: 1:45pm-3:15pm

Location: Les Muses Terrace, Level 3

Objective: To describe a case of genetically confirmed Fragile X syndrome presenting with levodopa unresponsive Parkinsonism

Background: Parkinsonism with or without ataxia is well recognised to occur with the premutation expansion of FMR1 gene whereas this is not a recognised clinical presentation for people with the full FMR1 mutation causing Fragile X syndrome. The pathophysiology in cases with premutation is speculated to be a toxic gain-of-function messenger RNA (mRNA) manifesting with the features of fragile X associated ataxia syndrome (FXTAS). The full expansion leads to Fragile X syndrome; a condition predominantly affecting males and manifests with learning disability, autism and epilepsy. Patients who have genetic mosaicism or who have not fully methylated mutations may still express elevated mRNA.

Method: Case report

Results: A 62 year old presented to the outpatient department with a 12 month history of deteriorating mobility described as an increasing frequency of falls and dragging of his right leg. He had a lifelong history of severe learning disability and had two male siblings with learning disability and autism. Examination revealed unilateral rigidity with cogwheeling and bradykinesia, no tremor and normal power and reflexes. His Parkinsonism was managed initially with escalating doses of levodopa. After failing to respond to levodopa, genetic testing was performed identifying full mutation in FMR1 diagnosing Fragile X syndrome.

Conclusion: This is an unusual case of genetically confirmed Fragile X syndrome in a patient who presented with a levodopa unresponsive parkinsonism in later life. This case appears to expand the clinical phenotype for Fragile X and suggests that there may be an alternate hypothesis to explain the gene to phenotype mechanism. As FMR1 mutations were first described only less than 30 years ago, we may start to see more patients manifesting with hitherto unrecognised neurological presentations in later life. Patients who present with parkinsonism and a strong family history of learning disability and autism may benefit from genetic testing for FMR1 mutation.

References: Jacquemont, S., Hagerman, R. J., Hagerman, P. J., & Leehey, M. A. (2007). Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurology, 6(1), 45-55

To cite this abstract in AMA style:

J. Mayer, J. Panicker, S. Alusi. Fragile X syndrome presenting with levodopa unresponsive parkinsonism [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/fragile-x-syndrome-presenting-with-levodopa-unresponsive-parkinsonism/. Accessed May 12, 2025.
  • Tweet
  • Email
  • Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/fragile-x-syndrome-presenting-with-levodopa-unresponsive-parkinsonism/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • VIT-D and Tics Movement Disorder
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley